Brk Antibody (D-6): sc-166243

Brk Antibody (D-6) is a mouse monoclonal IgG2a antibody that detects Brk in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Brk, also known as breast tumor kinase or PTK6, is a non-receptor tyrosine kinase that plays a pivotal role in various cellular processes, including cell proliferation, survival, and motility, by modulating signal transduction pathways. Brk′s unique structure features N-terminal SH3 and SH2 domains, which are essential for interaction with other proteins and for mediating downstream signaling events. Notably, Brk is predominantly expressed in epithelial tissues, particularly in the layers just above the proliferative cell zone in the skin and the lining of the alimentary canal, highlighting its importance in maintaining tissue integrity and function. Brk expression is significantly elevated in many breast carcinomas, while absent in normal breast tissue, suggesting a potential role in tumorigenesis. Furthermore, Brk′s ability to undergo autophosphorylation is crucial for regulatory mechanisms, influencing activity and interactions with other signaling molecules. anti-Brk antibody (D-6) serves as an invaluable tool for researchers investigating the molecular underpinnings of cancer and epithelial biology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Brk Antibody (D-6) References:

1. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition.  |  Qiu, H. and Miller, WT. 2002. J Biol Chem. 277: 34634-41. PMID: 12121988
2. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.  |  Derry, JJ., et al. 2003. Oncogene. 22: 4212-20. PMID: 12833144
3. Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.  |  Chen, HY., et al. 2004. Mol Cell Biol. 24: 10558-72. PMID: 15572663
4. Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.  |  Ikeda, O., et al. 2010. J Biol Chem. 285: 38093-103. PMID: 20929863
5. Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.  |  Ikeda, O., et al. 2011. Cancer Sci. 102: 756-61. PMID: 21205088
6. BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.  |  Miah, S., et al. 2014. PLoS One. 9: e87684. PMID: 24523872
7. Brk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4.  |  Patel, P., et al. 2015. Mol Cell Biol. 35: 1506-22. PMID: 25733683
8. Novel 4-anilino-α-carboline derivatives induce cell death in nonadhesive breast cancer cells through inhibition of Brk activity.  |  Oelze, M., et al. 2015. Int J Clin Pharmacol Ther. 53: 1052-5. PMID: 26396134
9. Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.  |  Regan Anderson, TM., et al. 2016. Cancer Res. 76: 1653-63. PMID: 26825173
10. Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.  |  Regan Anderson, TM., et al. 2018. Mol Cancer Res. 16: 1761-1772. PMID: 29991529

The preferred Brk antibody is Brk Antibody (D-7): sc-137045.